FDA approves Opdivo in second-line bladder cancer: http://finance.yahoo.com/news/bristol-myers-squibb-receives-fda-211500753.html This is an accelerated approval based on the 20% RR (including a 3% CR rate) in the single-arm CHECKMATE-275 study.